Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

52.59 +0.96 (+1.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Thera

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
1 Little-Known Vanguard Index Fund to Buy Before It Soars 50%, According to a Wall Street Analyst
Tom Lee of Fundstrat Global Advisors thinks the small-cap Russell 2000 could climb 50% by the end of 2024. 
Via The Motley Fool
Viking Therapeutics Unusual Options Activity
Via Benzinga
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
VKTX Stock Earnings: Viking Therapeutics Beats EPS for Q1 2024
VKTX stock results show that Viking Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Looking At Viking Therapeutics's Recent Unusual Options Activity
Via Benzinga
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Viking Therapeutics's Options: A Look at What the Big Money is Thinking
Via Benzinga
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the... 
Via Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
Via InvestorPlace
3 Red-Hot Biotech Rockets Blasting Off in 2024
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits. 
Via InvestorPlace
Topics Economy
Exposures Economy
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
Is it Too Late to Buy Viking Therapeutics Stock?
Viking Therapeutics stock is on fire following a successful phase 2 trial for its obesity care candidate. 
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
This Vanguard growth fund is home to some of the world's most innovative companies. 
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth. 
Via InvestorPlace
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
Viking Therapeutics: Strong Results In Obesity
With a potential best in class drug for oral and injectable use, Viking Therapeutics has to be on many Big Pharma/Bio acquisition wish lists, as the company represents a very scarce asset in the $100... 
Via Talk Markets
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great. 
Via The Motley Fool
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now. 
Via InvestorPlace
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments. 
Via InvestorPlace
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
These rising drugmakers have serious arguments in their favor. 
Via The Motley Fool
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate. 
Via The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
Exposures Product Safety
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Shares of the clinical-stage biotech have skyrocketed on recent good news. 
Via The Motley Fool
MarketBeat Week in Review – 4/1 - 4/5
Equities lost ground this week as investors consider the effect of fewer rate cuts, rising oil prices, and robust job gains ahead of a new earnings season 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
These businesses should see good times ahead. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.